Mechanisms and therapeutic implications of angiogenesis

Current Opinion in Oncology

Volumn 8, Issue 1, 1996, Pages 60-65

  Bicknell, Roy ^a   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; CELL ADHESION MOLECULE; METALLOPROTEINASE INHIBITOR; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN P53; PROTEIN TYROSINE KINASE; THYMIDINE PHOSPHORYLASE; UROKINASE; VASCULOTROPIN;

ANGIOGENESIS; CLINICAL TRIAL; HUMAN; KAPOSI SARCOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR GROWTH;

EID: 0029961624     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199601000-00011     Document Type: Review

References (75)

1. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao YH, Sage EH, Folkman J: Angiostatin: a novel angiogenesis Inhibitor that mediates the suppression of metastases by a Lewis lung-carcinoma. Cell 1994, 79:315-328. This paper tests the hypothesis that tumors produce both angiogenic and antiangiogenic factors, and that the latter may restrain growth of metastases. If clinically confirmed, it has major implications in patient treatment.
2. Holmgren L, O'Rielly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995, 1:149-153.
3. van Meir EG, Polverini PJ, Chazin VR, Su Huang H -J, de Tribolet N, Cavanee WK: Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genet 1994, 8:171-176.
4. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164. Newly growing and migrating blood vessels express the alpha v beta 3 integrin and this study shows a clear link between signaling from the extracellular matrix and survival of new endothelial cells.
5. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ: Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995, 376:517-519.
6. Ishikawa K, Miyazono U, Hellman H, Drexler C, Wernstedt K, Hagiwara K, Usuki F, Takaku K, Risau W, Heldin CH: Identification of the angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989, 338:557-562.
7. Moghaddam A, Bicknell R: Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 1992, 31:12141-12146.
8. Finnis C, Dodsworth N, Pollitt CE, Carr G, Sleep D: Thymidine phosphorylase activity of platelet-derived endothelial cell growth factor is responsible for endothelial cell mitogenicity. Eur J Biochem 1993, 212:201-210.
9. Usuki J, Saras J, Waltenberger K, Miyazono K, Pierce G, Thomason A, Heldin C-H: Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophys Res Commun 1992, 184:1311-1316.
10. Moghaddam A, Zhang H -T, Fan T -PD, Hu D-E, Lees V, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R: Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A 1995, 92:998-1002.
11. Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y, Akiyama S-I: Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 1995 55:1687-1690.
12. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL: Different angiogenic pathways characterise superficial and invasive bladder cancer. Cancer Res 1995, 55:510-513.
13. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumour angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 84:1875-1887.
14. Bosari S, Lee AKC, DeLellis RA, Wiley BD, Heatley GJ, Silverman KL: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992, 23:755-761.
15. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet-endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992, 340:1120-1124.
16. Axelsson K, Ljung B-ME, Moore DH II, Thor AD, Chew KL, Edgerton SM, Smith HS, Mayall BH: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995, 87:997-1008.
17. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL: Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count and computer image analysis. J Pathol 1995, 177:275-283. There have been problems reproducing vessel counts, and this study shows that the Chalkley count method gives reproducible results similar to image analysis.
18. Yamazaki K, Abe S, Takekawa H, Sukoh N, Watanabe N, Ogura S, Nakajima I, Isobe H, Inoue K, Kawakami Y: Tumour angiogenesis in human lung adenocarcinoma. Cancer 1994, 74:2245-2250.
19. Pili R, Guo Y, Chang J, Nakanishi H, Martin GR, Passanti A: Altered angiogenesis underlying age-dependent changes in tumour growth. J Natl Cancer Inst 1994, 86:1303-1314.
20. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL: Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994, 74:762-766.
21. Fox S, Leek R, Smith K, Hollyer J, Greenall M, Harris A: Tumor angiogenesis in node negative breast carcinomas: relationship to epidermal growth factor receptor and survival. Breast Cancer Res Treat 1994, 29:109-116.
22. Li V, Folkerth R, Watanabe H, Yu C, Rupnick M, Barnes P, Scott R, Black P, Sallan S, Folkman J: Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994, 344:82-86. The measurement of an angiogenic factor in cerebrospinal fluid was related to tumor angiogenesis and has implications for monitoring and treating patients with brain tumors.
23. Wesseling P, van der Laak JA, de Leeuw H, Ruiter DJ, Burger PC: Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme: computer assisted image analysis of whole tumor sections. J Neurosurg 1994, 81:902-909.
24. Saclaides TJ, Speziale NJ, Drab E, Szeluga DJ, Rubin DB: Tumour angiogenesis and rectal carcinoma. Dis Colon Rectum 1994, 37:921-926.
25. Olivarez D, Ulbright T, Deriese W, Foster R, Reister T, Einhorn L, Sledge G: Neovascularisation in clinical stage A testicular germ cell tumour: prediction of metastatic disease. Cancer Res 1994, 54:2800-2802.
26. Vermeulen PB, Verhoeven D, Hubens G, Vanmarck E, Goovaerts G, Huyghe M, Dehruijn EA, Vanoosterom AT, Dirix LY: Microvessel density, endothelial cell proliferation and tumour cell proliferation In human colorectal adenocarcinomas. Ann Oncol 1995, 6:59-64.
27. Leedy DA, Trune DR, Kronz JD, Weidner N, Cohen JI: Tumour angiogenesis, the p53 antigen, and cervical metastasis In squamous carcinoma of the tongue. Placenta 1994, 111:417-422
28. Wiggins DL, Granai CO, Steinhoff MM, Calabresi P: Tumour angiogenesis as a prognostic factor in cervical carcinoma. Gynaecol Oncol 1995, 56:353-356.
29. Toi M, Hoshina S, Takayanagi T, Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994, 85.1045-1049.
30. Bicknell R: Vascular targeting and the inhibition of angiogenesis. Ann Oncol 1994, 5:45-50. This report contrasts antiangiogenesis and vascular targeting and provides a core review on vascular targeting.
31. Fan T-PD Jaggar R, Bicknell R: Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 1995, 16:57-66. This article provides a critical assessment of anti-angiogenic and vascular targeting strategies.
32. Herndier BG, Werner A, Arnstein P, Abbey NW, Demartis F, Cohen RL, Shuman MA, Levy JA: Characterisation of a human Kaposi's sarcoma cell line that induces angiogenic tumours in animals. AIDS 1994, 8:575-581.
33. Kato T, Sato K, Kakinuma H, Matsuda Y: Enhanced suppression of tumour growth by combination of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994, 54:5143-5147.
34. Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN, Brem H: Potentiation of cytotoxic cancer therapies by tnp-470 alone and with other anti-angiogenic agents. Int J Cancer 1994, 57:920-925. The work of this group in several publications has shown the significant improvements in antitumor effects obtained by combining multiple antiangiogenic agents with chemotherapy.
35. Strugar J, Rothbart D, Harrington W, Criscuolo GR: Vascular permeability factor in brain metastases: correlation with vasogenic brain oedema and tumour angiogenesis. J Neurosurg 1994, 81:560-566.
36. Abramovitch R, Meir G, Neeman M: Neovascularisation induced growth of Implanted C6 glioma multicellular spheroids: magnetic resonance microimaging. Cancer Res 1995, 55:1956-1962.
37. Sasajima T, Mineura K, Sasaki J, Kowada M, Tomura N, Hatazawa J, Ogawa T, Uemura K: Positron emission tomographic assessment of cerebral hemocirculation and glucose metabolism in malignant glioma following treatment with intracarotid recombinant human tumour necrosis factor-alpha. J Neuro Oncol 1995, 23:67-73.
38. Reynolds K, Farzaneh F, Collins WP, Campbell S, Bourne TH, Lawlon F, Moghaddam A, Harris AL, Bicknell B: Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst 1994, 86:1234-1238. The correlation of increased tumor blood flow measured by color Doppler with various angiogenic factors was studied, and platelet-derived endothelial cell growth factor was most closely related to blood flow.
39. Scopinaro F, Schillaci O, Scarpini M, Mingazzini PL, Di-Macio L, Banci M, Danieli R, Zerilli M, Limiti MR, Centi-Colella A: Technetium sestamibi: an indicator of breast cancer invasiveness. Eur J Med Med 1994, 21:984-987.
40. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994, 86:356-361. The ability to monitor antiangiogenesis therapy will be essential in future trials, and this study shows that urine basic fibroblast growth factor may be a suitable marker.
41. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995, 26:86-91. This paper demonstrated upregulation of both receptors and ligands, and it emphasizes the importance of the VEGF pathway in tumor angiogenesis.
42. Plate KH, Breier G, Weich HA, Mennel HD, Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994, 59:520-529.
43. Czubayko F, Smith RV, Chung HC, Wellstein A: Tumour growth and angiogenesis induced by a secretal binding protein for fibroblast growth factors. J Biol Chem 1994, 269:28243-28248. A novel mechanism for a growth factor pathway is described, facilitating the effect of basic fibroblast growth factor and providing a possible way for a protein without a leader sequence to reach the extracellular matrix.
44. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T: Expression of platelet-derived endothelial cell growth factor thymidine phosphorylase in human breast cancer. Int J Cancer 1995, 64:79-82.
45. Takahashi A, Sasaki HK, Kim SJ, Tobisu K, Kalkizoe T, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994, 54:4233-4237.
46. Kaipainen A, Vlaykova T, Hatva E, Bohling T, Jekunen A, Pyrhonen S, Alitalo K: Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res 1994, 54:6571-6577.
47. Vartanian RK, Weidner N: Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor anglogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 1994, 144:1188-1194.
48. Fox SB, Gatter KC, Bicknell R, Going JJ, Stanton P, Cooke TG, Harris AL: Relationship of endothelial cell proliferation to tumour vascularity In human breast cancer. Cancer Res 1993, 53:4161-4163.
49. Ganesh S, Sier CFM, Griffioen G, Vloedgraven HJM, Verheijen JH, Lamers CB, Verspaget HW: Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994, 54:4065-4071.
50. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dano K, Grondahlhansen J: Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator Inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994, 54:4671-4675.
51. Janicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H: Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic Impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994, 54:2527-2530. The methodology of assessing urokinase is important for comparison between studies because it is a strong predictor of poor outcome in many tumor types.
52. Solberg H, Romer J, Brunner N, Holm A, Sidenius N, Dano K, Hoyerhansen G: A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murlne tumours. Int J Cancer 1994, 58:877-881.
53. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L: The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994, 59:612-618. This variant is expressed in fetal vessels and becomes expressed in tumor angiogenesis and wound healing.
54. Sers C, Riethmuller G, Johnson JP: MUC18, a melanoma-progression associated molecule, and its potential role in tumour vascularization and hematogenous spread. Cancer Res 1994, 54:5689-5694.
55. Galardy RE, Grobelny D, Foellmer HG, Fernandez LA: Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2-(hydroxamidocarbonymethyl)-4-methylpentanoyl)]-L-tryptophan methylamide. Cancer Res 1994, 54:4715-4718.
56. Mueller BM, Yu YB, Laug WE: Overexpression of plasminogen activator inhibitor 2 in human melanoma cell inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci U S A 1995, 92:205-209.
57. Johnson MD, Kim HR, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994, 160:194-202.
58. Gagliardi AR, Collins DC: Inhibition of angiogenesis by aurintricarboxylic acid. Anticancer Res 1994, 14:475-479.
59. Voest EE, Kenyon BB, O'Reilly MS, Truitt G, Damato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995, 87:581-586. Interleukin-12 is undergoing clinical trials and may be an important drug for use in combination with chemotherapy or immune therapy.
60. Kumazawa E, Akimoto T, Kita Y, Jimbo T, Joto N, Tohgo A: Intratumoral production of tumour necrosis factor augmented by endogenous interferons results in potent antltumour effects of DT-5461, a synthetic lipid A analog. J Immunother 1995, 17:141-150.
61. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994, 91:4082-4085.
62. Borgstrom P, Torres-Fiho IP, Vajkoczy P, Strandgarden K, Polacek J, Hartley-Asp B: The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo. Cancer Chemother Pharmacol 1994, 34:280-286.
63. Norioka K, Mitaka T, Mochizuki Y, Hara M, Kawagoe M, Nakamura H: Interaction of interleukin-1 and interferon-gamma on fibroblast growth factor induced angiogenesis. Jpn J Cancer Res 1994, 85:522-529.
64. Moore DM, Kalvakolanu DV, Lippman SM, Kavanagh JJ, Hong WK, Borden EC, Paredes-Espinoza M, Krakoff IH: Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol 1994, 31:31-37.
65. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM: Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 1995, 36:83-87.
66. Olson KA, Fett JW, French TC, Key ME, Vallee BL: Angiogenin antagonists prevent tumour growth in vivo. Proc Natl Acad Sci U S A 1995, 92:442-446. The mechanism of action of angiogenin is unknown, although it has homology to ribonucleases. The in vivo effect suggests that angiogenesis may be a worthwhile therapy target.
67. Ensoli B, Markham P, Kao V, Barillari G, Fiorelli V, Gendelman R, Raffeld M, Zon G, Gallo RC: Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis and lesion formation In nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. J Clin Invest 1994, 94:1736-1746.
68. Baba M, Shigeta S, Ikeuchi T, Korenaga H, Osada Y: Anti-angiogenesis agent DS 4152 is a potent and selective inhibitor of HIV-1 replication in vivo. AIDS 1994, 8:43-48.
69. Braddock PS, Hu DE, Fan T-PD, Stratford U, Harris AL, Bicknell R: A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Br J Cancer 1994, 69:890-898.
70. Kanoh T, Matsunaga K, Saito K, Fujii T: Suppression of in vivo tumour-induced angiogenesis by the protein bound polysaccharide PSK. In Vivo 1994, 8:247-250.
71. Sato K, Mochizuki M, Saiki I, Yoo YC, Samukawa K, Azuma I: Inhibition of tumour angiogenesis and metastasis by a saponin of Panax ginseng, ginsenoside-Rb2. Biol Pharm Bull 1994, 17:335-639.
72. Antoine N, Greimers R, De-Roanne C, Kusaka M, Heinen E, Simar LJ, Castronovo V: AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 1994, 54:2073-2076. AGM-1470 has a marked selectivity for endothelial cells. The target of the drug remains unclear, but this evidence suggests that signaling via the G1 checkpoint may be involved.
73. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, Ledda F: Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994, 94:2036-2044. If nitric oxide is a major pathway by which different growth factors function, inhibitors of nitric oxide synthase would be of interest for antiangiogenesis therapy.
74. Weinstat-Saslow DL, Zabrenetzky VS, Van Houtte K, Frazier WA, Roberts DD, Steeg PS: Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumorgrowth, metastatic potential and angiogenesis. Cancer Res 1994, 54:6504-6511. Thrombospondin production has been shown to be regulated by wild-type p53 and to inhibit angiogenesis. This experiment shows its role in several other processes associated with angiogenesis.
75. Greer P, Haigh J, Mbamalu G, Khoo W, Bernstein A, Pawson T: The Fps/Fes protein tyrosine kinase promotes angiogenesis in transgenic mice. Mol Cell Biol 1994, 14:6755-6763.